Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.95

€0.95

-3.080%
-0.03
-3.080%
-
 
13.09.24 / Stuttgart Stock Exchange WKN: A3DWEJ / Symbol: CLSN / Name: Celsion / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Celsion Corp. Stock

Heavy losses for Celsion Corp. today as the stock fell by -€0.030 (-3.080%).
For the coming years our community has positive and negative things to say abot the Celsion Corp. stock. Criterium "Company culture" gathered the most positive votes but regarding "Shareholder structure" there were negative voices in the community.

Pros and Cons of Celsion Corp. in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Celsion Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Celsion Corp. -3.080% 3.846% 6.780% -9.135% 58.824% -92.317% -95.842%
India Globalization Capital - 5.000% -20.541% -15.517% 12.214% -75.802% -69.053%
Protara Therapeutics Inc. 6.490% -2.381% -3.529% -9.392% -2.959% -72.437% -
CEL-SCI Corp. 2.040% 16.734% 11.208% -1.624% -55.388% -87.833% -83.299%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Celsion Corporation (NASDAQ: CLSN) occupies an intriguing spot in the Biotechnology and Medical Research sector, but a closer look at its financials unveils a complex narrative. The company's market capitalization is approximately $15.23 million, indicating it’s relatively small in comparison to industry giants. The negative EBITDA of approximately -$20 million raises immediate concerns about profitability and operational efficiency. Although Celsion holds potential in medical innovation, the financial metrics suggest a company grappling with the harsh realities of biopharmaceutical development, which often involves prolonged periods of investment before revenue generation.

Let's delve deeper into the financial landscape of Celsion, highlighting both the advantages and challenges it faces.

Market Presence and Innovation Potential: Celsion operates in an exciting arena, with a focus on innovative treatments. Companies positioned in this way could potentially see significant rewards if their products succeed in clinical trials or garner FDA approval. Investing in biotechnology can be akin to betting on the future of medicine, and Celsion’s pipeline may present opportunities for substantial market impact.